aiwiki.page
English

Acromegaly

Acromegaly is a hormonal disorder caused by prolonged growth hormone excess in adults, usually from a pituitary tumor, leading to tissue enlargement and systemic complications.

22 keywords1 linked from7 not yet writtenWritten by AI
HypothalamusSomatostatinInsulinInsulin Resistan…Joint painOsteoporosisHeadacheDiabetes Mellitu…Acromegaly

Acromegaly is a chronic endocrine disorder caused by excessive secretion of growth hormone after the growth plates of the long bones have closed. It produces progressive enlargement of the hands, feet, facial bones, and soft tissues, together with metabolic and cardiovascular effects. Most cases arise from a growth-hormone-secreting pituitary adenoma, usually a noncancerous tumor. Much of the tissue overgrowth is mediated by increased insulin-like growth factor 1 (IGF-1). The equivalent hormonal excess before growth-plate closure causes gigantism, characterized by excessive linear growth; the two conditions can overlap when hormone excess begins during adolescence.

Hormonal mechanism and causes

Growth hormone is produced by somatotroph cells in the pituitary gland, which lies beneath the brain. Its secretion is normally pulsatile and is regulated by signals from the hypothalamus. Growth-hormone-releasing hormone stimulates secretion, while somatostatin inhibits it. Growth hormone stimulates production of IGF-1 in the liver and other tissues; IGF-1 mediates many of its growth-promoting effects and contributes to negative feedback on hormone secretion.

In acromegaly, a pituitary tumor secretes growth hormone despite these normal feedback mechanisms. Persistently increased growth hormone and IGF-1 promote soft-tissue growth, bone remodeling, and enlargement of some internal organs. Growth hormone also opposes several actions of insulin, contributing to insulin resistance and disturbances of glucose regulation.

Most causative tumors occur sporadically. A minority arise in association with inherited predispositions, including multiple endocrine neoplasia type 1 and familial isolated pituitary adenoma. Some inherited forms present at younger ages.

Rarely, a tumor outside the pituitary produces excess growth-hormone-releasing hormone, stimulating pituitary growth and growth hormone secretion. Direct secretion of growth hormone by a nonpituitary tumor is exceptionally uncommon. These mechanisms matter because their investigation and treatment differ from those of a primary pituitary tumor.

Clinical features

Acromegaly generally develops gradually over years. Early changes may be subtle, and diagnosis can be delayed because individual symptoms are common in other conditions.

Changes in appearance and soft tissues

Characteristic findings include:

  • Enlargement of the hands and feet, reflected in increasing ring or shoe size.
  • Thickening of facial features, with prominence of the brow and enlargement of the nose and lips.
  • Enlargement and forward projection of the lower jaw, sometimes with increased spacing between teeth.
  • Thickened skin, increased sweating, and oily skin.
  • Enlargement of the tongue and deepening of the voice.

After growth plates have closed, growth hormone excess does not substantially increase height. Instead, bones thicken and soft tissues enlarge. Comparison with older photographs can make slowly developing facial changes more apparent.

Musculoskeletal and neurological effects

Joint enlargement and altered cartilage and bone structure can produce stiffness, reduced movement, and joint pain. Established joint damage may persist despite hormonal control. Soft-tissue thickening can compress peripheral nerves, particularly the median nerve at the wrist, causing carpal tunnel syndrome.

Skeletal changes can also affect the spine. Vertebral fractures may occur even when conventional bone-density measurements do not show osteoporosis.

Effects of the pituitary tumor

The tumor itself can cause headache. Upward extension may compress the optic chiasm, producing visual-field loss, classically affecting the outer fields of both eyes.

Compression of normal pituitary tissue can reduce production of other pituitary hormones. Some tumors also secrete prolactin. Resulting manifestations may include menstrual disturbance, reduced sexual function, infertility, or deficiencies of thyroid and adrenal hormone regulation.

Associated conditions and complications

Acromegaly affects multiple organ systems rather than only physical appearance.

  • Metabolic disease: Insulin resistance can lead to impaired glucose tolerance or diabetes mellitus.
  • Cardiovascular disease: Hypertension, enlargement and thickening of the heart muscle, valve abnormalities, and rhythm disturbances can occur. Advanced cardiac involvement may contribute to heart failure.
  • Sleep-disordered breathing: Enlargement of the tongue and upper-airway soft tissues contributes to obstructive sleep apnea, which may persist after biochemical control.
  • Colorectal abnormalities: Colorectal polyps occur more frequently in people with acromegaly. Increased risk of colorectal cancer has also been reported, although estimates vary among studies.
  • Functional burden: Joint disease, fatigue, altered appearance, and other persistent symptoms can impair health-related quality of life.

The severity of complications is influenced by the duration and degree of hormone excess, tumor characteristics, and coexisting disease.

Diagnosis

Diagnosis combines clinical findings with biochemical testing. Imaging identifies the source of hormone excess but does not establish acromegaly by itself.

IGF-1 measurement

Serum IGF-1 is the principal initial biochemical marker because it reflects growth hormone activity more consistently than a single growth hormone measurement. Results are interpreted against age-adjusted reference ranges.

Interpretation requires attention to the laboratory assay and to conditions that alter IGF-1 concentrations, including poor nutritional status, liver disease, poorly controlled diabetes, and oral estrogen use. Borderline or discordant results may require repeat measurement and further assessment.

Growth hormone testing

A single random growth hormone measurement is difficult to interpret because normal secretion is pulsatile and influenced by sleep, exercise, stress, and metabolic state.

An oral glucose suppression test can help clarify the diagnosis. In people without acromegaly, glucose administration normally suppresses growth hormone secretion. Failure of appropriate suppression supports the diagnosis in the relevant clinical and biochemical context. Diagnostic thresholds depend on the assay and clinical circumstances; the test is not necessary in every unequivocal case.

Imaging and assessment of tumor effects

Magnetic resonance imaging of the pituitary is used to locate the tumor and determine its size and relationship to surrounding structures. Visual-field testing evaluates possible optic pathway compression. Additional hormone measurements assess the function of the remaining pituitary tissue.

When biochemical acromegaly is present without a convincing pituitary lesion, investigation may consider a nonpituitary source of growth-hormone-releasing hormone.

The differential diagnosis includes conditions that cause acromegaly-like physical features without growth hormone excess, sometimes termed pseudoacromegaly. Biochemical testing distinguishes these appearances from true acromegaly.

Treatment

Treatment aims to normalize IGF-1 and control growth hormone excess, remove or reduce the tumor, preserve pituitary function, and limit complications. The main approaches are surgery, medication, and radiation therapy, often used in combination.

Surgery

Transsphenoidal surgery removes the pituitary tumor through an approach via the nose and sphenoid sinus. It is the usual first treatment for many surgically accessible tumors, particularly when complete removal appears feasible or nearby structures are compressed.

The likelihood of biochemical remission depends on tumor size, invasion of surrounding structures, hormone levels, and surgical expertise. Possible complications include cerebrospinal fluid leakage, disturbances of water balance, and loss of normal pituitary hormone function.

Medication

Several drug classes act at different points in the growth hormone–IGF-1 pathway:

  • Somatostatin receptor ligands, including octreotide, lanreotide, and pasireotide, suppress growth hormone secretion and can reduce tumor size. Their effects on glucose regulation differ; pasireotide can cause substantial hyperglycemia.
  • Pegvisomant, a growth hormone receptor antagonist, blocks growth hormone action and lowers IGF-1. It does not directly suppress tumor secretion, so IGF-1 rather than growth hormone is used to assess its biochemical effect.
  • Cabergoline, a dopamine receptor agonist, can reduce hormone excess in some patients, particularly when biochemical elevations are relatively modest or the tumor also secretes prolactin.

Medication may be used for persistent disease after surgery, when surgery is unsuitable, or as part of combination treatment.

Radiation therapy

Radiation therapy, including stereotactic techniques, can control residual tumor and gradually reduce hormone secretion when other approaches do not provide adequate control. Its hormonal effects may take years, and medication is often needed during that interval. Delayed loss of pituitary hormone function is an important long-term consequence.

Course and long-term follow-up

Untreated or persistently active acromegaly is associated with increased illness and premature mortality, particularly through cardiovascular, respiratory, and metabolic complications. Effective biochemical control substantially improves long-term outcomes.

Soft-tissue swelling, sweating, and some metabolic abnormalities often improve after successful treatment. Established bony changes, joint damage, and some airway or cardiac abnormalities may not fully reverse.

Long-term follow-up assesses hormone levels, residual or recurrent tumor, pituitary function, and associated conditions. Biochemical remission does not necessarily mean that all symptoms or complications have resolved, and recurrence can occur after initially successful surgery.

Historical background

The French physician Pierre Marie described acromegaly as a distinct clinical condition in 1886. The name derives from Greek words referring to enlargement of the extremities. Subsequent recognition of its association with pituitary tumors, followed by identification of growth hormone and IGF-1 physiology, established the basis for modern biochemical diagnosis and targeted treatment.